Why the study?
What is the safety and efficacy of oral medications for the management of patent ductus arteriosus in preterm infants?
What is the safety and efficacy of oral medications for the management of patent ductus arteriosus in preterm infants?
Answers are grounded in this paper and cite their sources.
Oral ibuprofen is preferred for PDA closure in preterm infants due to superior efficacy over intravenous administration and better safety than indomethacin, with paracetamol emerging as a safer alternative.
Patent ductus arteriosus (PDA) is a common clinical condition in preterm infants which is inversely related to birth weight and gestational age. Cyclooxygenase inhibitors such as indomethacin and ibuprofen which block the prostaglandin conversion from arachidonic acid are the most commonly used drugs for ductal closure. This review focuses on the safety and efficacy oral medications in the management of PDA in preterm infants. Ibuprofen seems to be the first choice due to its higher safety profile, as it is associated with fewer gastrointestinal and renal side effects when compared to indomethacin. PDA closure rates are better with oral than with intravenous ibuprofen probably due to the pharmacokinetic of the drug. However, these medications were reported to be associated with several adverse including transient renal failure, gastrointestinal bleeding and perforation, hyperbilirubinemia and platelet dysfunction. Paracetamol seems be an alternative to PDA therapy with lower adverse events and side effects.
No takes yet. Share an insight, caveat, or question.
Mehmet Yekta Öncel (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: